Related references
Note: Only part of the references are listed.International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013
Joannie Lortet-Tieulent et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013
Joannie Lortet-Tieulent et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2
Angel Chao et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2018)
Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias
Maria Alba Dosil et al.
JOURNAL OF PATHOLOGY (2017)
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
Tomohito Tanaka et al.
PLOS ONE (2017)
Targeting CDK4/6 in patients with cancer
Erika Hamilton et al.
CANCER TREATMENT REVIEWS (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecules that target nucleophosmin for cancer treatment: an update
Adele Di Matteo et al.
ONCOTARGET (2016)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
Phosphorylation of Nucleophosmin at Threonine 234/237 is associated with HCC metastasis
Rachel Hiu Ha Ching et al.
ONCOTARGET (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23)
Angel Chao et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
Siming Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Cdk2 and Cdk4 Regulate the Centrosome Cycle and Are Critical Mediators of Centrosome Amplification in p53-Null Cells
Arsene M. Adon et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Dephosphorylation of Nucleophosmin by PP1β Facilitates pRB Binding and Consequent E2F1-dependent DNA Repair
Chiao Yun Lin et al.
MOLECULAR BIOLOGY OF THE CELL (2010)
Nucleophosmin Phosphorylation by v-Cyclin-CDK6 Controls KSHV Latency
Grzegorz Sarek et al.
PLOS PATHOGENS (2010)
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer
Vincent Jongen et al.
GYNECOLOGIC ONCOLOGY (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23
Sandeep S. Negi et al.
JOURNAL OF CELL SCIENCE (2006)
Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing
P Tarapore et al.
FEBS LETTERS (2006)
The role of nucleophosmin in centrosome duplication
M Okuda
ONCOGENE (2002)
The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype
M Okuwaki et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Share Paper
